The pharmaceutical industry is highly dependent on small innovator companies to fill late-stage pipeline needs. As a result, innovators are focused on achieving hPOC to monetize their development investment through a transaction with a biopharma partner or an IPO.

The pharmaceutical industry is highly dependent on small innovator companies to fill late-stage pipeline needs. As a result, innovators are focused on achieving hPOC to monetize their development investment through a transaction with a biopharma partner or an IPO.

The pharmaceutical industry is highly dependent on small innovator companies to fill late-stage pipeline needs. As a result, innovators are focused on achieving hPOC to monetize their development investment through a transaction with a biopharma partner or an IPO.